Advertisement
UK markets close in 3 hours 7 minutes
  • FTSE 100

    8,229.43
    +24.32 (+0.30%)
     
  • FTSE 250

    20,442.04
    +60.99 (+0.30%)
     
  • AIM

    773.81
    -3.69 (-0.47%)
     
  • GBP/EUR

    1.1829
    -0.0005 (-0.05%)
     
  • GBP/USD

    1.2687
    -0.0035 (-0.27%)
     
  • Bitcoin GBP

    52,018.64
    +751.78 (+1.47%)
     
  • CMC Crypto 200

    1,374.35
    -8.32 (-0.60%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CRUDE OIL

    81.59
    +0.02 (+0.02%)
     
  • GOLD FUTURES

    2,351.90
    +5.00 (+0.21%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     
  • DAX

    18,156.54
    +88.63 (+0.49%)
     
  • CAC 40

    7,633.25
    +63.05 (+0.83%)
     

Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.

Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.

Gilead Sciences stock was climbing Friday on hopes that it would get into the obesity-drug game. GLP-1s, the technical name for the popular obesity drugs, has been one of the biggest drivers of pharmaceutical stocks in recent months. Which may be why Gilead stock has gained 2.8% to $64.55 in afternoon trading Friday after Jefferies released a note late Thursday night.